(2R,3S,4S,5R,6R)-2-((R)-1-((2S,3R,4R,5R)-4-acetoxy-5-(3-((benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate | 1158951-64-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: (2R,3S,4S,5R,6R)-2-((R)-1-((2S,3R,4R,5R)-4-acetoxy-5-(3-((benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
• 英文别名: (2R,3S,4S,5R,6R)-2-((1R)-1-((2S,5R)-4-acetoxy-5-(3-((benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
• CAS: 1158951-64-4
• 化学式: C₃₃H₄₁N₃O₁₇
• 分子量: 751.698
• InChiKey: PEBIBDPDUCFSMX-UQPSMJSKSA-N

物化性质

• 沸点：
  834.3±75.0 °C(predicted)
• 密度：
  1.45±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.59
• 重原子数：
  53.0
• 可旋转键数：
  15.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  258.67
• 氢给体数：
  2.0
• 氢受体数：
  19.0

反应信息

• 作为反应物：
  描述：

  (2R,3S,4S,5R,6R)-2-((R)-1-((2S,3R,4R,5R)-4-acetoxy-5-(3-((benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 在 甲醇 、 sodium chlorite 、 sodium dihydrogenphosphate dihydrate 、 2-甲基-2-丁烯 、 palladium 10% on activated carbon 、 氢气 、 三氧化硫吡啶 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 二甲基亚砜 、 异丙醇 、 叔丁醇 为溶剂， 反应 13.0h， 生成 (2S,3S,4S)-2-((1R)-2-amino-1-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
  参考文献：
  名称：

  DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors

  摘要：

  Capuramycin displays a narrow spectrum of antibacterial activity by targeting bacterial translocase I (MraY). In our program of development of new N-acetylglucosaminephosphotransferase1 (DPAGT1) inhibitors, we have identified that a capuramycin phenoxypiperidinylbenzylamide analogue (CPPB) inhibits DPAGT1 enzyme with an IC50 value of 200 nM. Despite a strong DPAGT1 inhibitory activity, CPPB does not show cytotoxicity against normal cells and a series of cancer cell lines. However, CPPB inhibits migrations of several solid cancers including pancreatic cancers that require high DPAGT1 expression in order for tumor progression. DPAGT1 inhibition by CPPB leads to a reduced expression level of Snail but does not reduce E-cadherin expression level at the IC50 (DPAGT1) concentration. CPPB displays a strong synergistic effect with paclitaxel against growthinhibitory action of a patient-derived pancreatic adenocarcinoma, PD002: paclitaxel (IC50: 1.25 mu M) inhibits growth of PD002 at 0.0024-0.16 mu M in combination with 0.10-2.0 mu M CPPB (IC50: 35 mu M).

  DOI：

  10.1021/acs.jmedchem.0c00545
• 作为产物：
  描述：

  4-METHYLPHENYL2,3,4,6-TETRA-O-ACETYL-1-THIO-Α-D-MANNOPYRANOSIDE4-甲基苯基2,3,4,6-四-O-乙酰基-1-硫代-Α-D-吡喃甘露糖苷 在 4-二甲氨基吡啶 、 strontium(II) carbonate 、 N-碘代丁二酰亚胺 、 silver tetrafluoroborate 、 乙醛肟 、 dichlorotetrakis(1,1- dimethylethyl)di-μ-hydroxyditin 、 硫脲 、 mercury dichloride 、 N,N'-二异丙基碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 69.0h， 生成 (2R,3S,4S,5R,6R)-2-((R)-1-((2S,3R,4R,5R)-4-acetoxy-5-(3-((benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
  参考文献：
  名称：

  DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors

  摘要：

  Capuramycin displays a narrow spectrum of antibacterial activity by targeting bacterial translocase I (MraY). In our program of development of new N-acetylglucosaminephosphotransferase1 (DPAGT1) inhibitors, we have identified that a capuramycin phenoxypiperidinylbenzylamide analogue (CPPB) inhibits DPAGT1 enzyme with an IC50 value of 200 nM. Despite a strong DPAGT1 inhibitory activity, CPPB does not show cytotoxicity against normal cells and a series of cancer cell lines. However, CPPB inhibits migrations of several solid cancers including pancreatic cancers that require high DPAGT1 expression in order for tumor progression. DPAGT1 inhibition by CPPB leads to a reduced expression level of Snail but does not reduce E-cadherin expression level at the IC50 (DPAGT1) concentration. CPPB displays a strong synergistic effect with paclitaxel against growthinhibitory action of a patient-derived pancreatic adenocarcinoma, PD002: paclitaxel (IC50: 1.25 mu M) inhibits growth of PD002 at 0.0024-0.16 mu M in combination with 0.10-2.0 mu M CPPB (IC50: 35 mu M).

  DOI：

  10.1021/acs.jmedchem.0c00545

文献信息

• Concise Synthesis of Capuramycin
  作者：Michio Kurosu、Kai Li、Dean C. Crick

  DOI：10.1021/ol900458w

  日期：2009.6.4

  A concise total synthesis of capuramycin (1), a promising preclinical TB drug lead, is achieved by high-yield formations of the cyanohydrin 5a and 4 '',5 ''-glycal derivative 12. Capuramycin can be synthesized in eight steps from the uridine building block 5a with >30% overall yield. The synthetic intermediates reported here are useful for generation of analogs to improve pharmacokinetic properties of capuramycin.